RRM2基因表达水平与乳腺癌术后复发的关系  

Correlation of ribonucleotide reductases M2 gene and recurrence-free survival in breast cancer

作　　者：岑东芝[1] 李伟明[1] 罗超元[1] 黄波[1] 

机构地区：[1]广州医学院第三附属医院肿瘤科,广州510150

出　　处：《安徽医科大学学报》2013年第4期416-419,共4页Acta Universitatis Medicinalis Anhui

基　　金：广东省科学技术协会项目(编号:GDKX201003);广州医学院第三附属医院项目(编号:2012Y14)

摘　　要：目的探讨核苷酸还原酶亚单位M2(RRM2)在乳腺癌组织中的表达水平及与乳腺癌术后无复发生存(RFS)的关系。方法利用BRB-Array Tools软件回顾性分析了124例乳腺癌患者组织中的RRM2基因表达水平;Kaplan-Meier法计算生存率,制作生存曲线,并采用Log-Rank进行检验,应用Cox比例风险回归模型行多因素分析。结果乳腺癌患者RRM2基因的高表达与肿瘤分化程度和雌激素受体(ER)状态高度有关(P<0.01),而与患者的年龄、有无淋巴结转移无关;生存分析提示:随着RRM2基因表达增加,乳腺癌RFS显著缩短(χ2=6.198,P<0.05);应用多因素Cox模型分析表明,RRM2基因表达水平是RFS(P<0.05,Exp(B)=1.376)独立的危险因素。结论 RRM2基因高表达的乳腺癌患者的术后复发风险增加。Objective To investigate the relationship between expression of ribonucleotide reductase subunit M2 （RRM2） and recurrence-free survival（RFS） in breast cancer. Methods Retrospective analysis was performed u- sing Affymetrix microarray data from n = 124 breast cancer patients to evaluate RRM2 expression. Follow-up data were handled by Kaplan-Meier survival analysis and multivariate Cox regression analysis. Results RRM2 expres- sion showed a strong correlation with tumor grade （ P 〈 0.01 ） as well as ER（ P 〈 0.01 ）. Survival analysis revealed a significant prognostic value for RFS （X2 = 6. 198, P 〈 0.05 ）. In multivariate Cox regression analysis including standard parameters, RRM2 emerged to be the top prognostic marker for RFS （P 〈0. 05 ,Exp（B） = 1. 376）. Con- cancer patients with higher RRM2 expression are more likely to have recurrences after surgery.

关 键 词：RRM2 GEO数据库 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]